Although PD‐L1 expression in gynecologic cancers is highly variable depending on tumor stage and molecular subtype, PD‐L1 is relatively overexpressed in these cancers and is associated with poor prognosis, making it a compelling therapeutic target.1 Here, CD274 is linked to female reproductive organ cancer.